The study found that terlipressin plus albumin is significantly more effective than midodrine and octreotide plus albumin in reversal of renal failure (55.5% vs 4.8%, P < .001) and improving renal function (70.4% vs 28.6%, P = .01) in patients with HRS.[6]. The gene discussed is ALB; the disease is acute kidney injury.